Loading clinical trials...
Loading clinical trials...
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Eli Lilly and Company
NCT06810505 · Chronic Migraine
NCT06241313 · Migraine
NCT07018713 · Chronic Migraine
NCT07454798 · Migraine, Headache Disorders, Primary
NCT06735833 · Migraine
Central Research Associates
Birmingham, Alabama
Rehabilitation & Neurological Services
Huntsville, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions